Skip to main content

IGC Pharma, Inc.

IGC
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001326205

No open-market purchases or sales by IGC Pharma, Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $1.41M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding IGC Pharma, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of IGC: Q3 2025 compared with Q4 2025
MeasureQ3 2025Of which not filed for Q4 2025Q4 2025Change
Holders35130−4
Shares5.44M18.5K4.83M−589.6K (−10.9%)
Value$2.27M$7.76K$1.36M−$899.2K (−39.8%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held IGC Pharma, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to IGC in Q4 2025
InstitutionSharesValue% of portfolio
Lawood & Co75,000$21.1K0.02%
T3 Companies, LLC20,000$5.63K0.01%
Jones Financial Companies LLLP110$310.00%
Root Financial Partners, LLC100$280.00%
Triumph Capital Management2$10.00%

Sold out (9)

Institutions that held IGC Pharma, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of IGC in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Virtu Financial LLC89,546$37.0K
HRT Financial LP60,258$25.0K
Two Sigma Securities, LLC35,028$14.6K
Gsa Capital Partners LLP27,821$12.0K
Thompson Davis & Co., Inc.10,000$4.17K
Baader Bank INC13,961$3.60K
Evermay Wealth Management LLC30$13
FMR LLC5$2
Simplex Trading, LLC212$0

Not filed for Q4 2025 yet (1)

Institutions that held IGC Pharma, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IGC in Q3 2025 that haven't filed for Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Wolverine Trading, LLC18,479$7.76K